TransCode Therapeutics (RNAZ) said Wednesday it has signed a deal with certain institutional investors for a securities' sale worth roughly $8 million.
The sale, which is expected to close Friday, includes about 21.2 million common shares, series C warrants to purchase about 21.2 million common shares, and series D warrants to purchase about 21.2 million common shares.
Net proceeds will be allocated towards working capital and general corporate purposes, the company said.
Shares of TransCode Therapeutics fell more than 9% in recent trading activity.
Price: 0.34, Change: -0.04, Percent Change: -9.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments